Protagonist Therapeutics PTGX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$130.15M-147% | $275.19M— | —— | -$127.39M-1.5% | ||
| $1.28M+55.0% | $826K-15.5% | $977K-5.5% | $1.03M+27.2% | ||
| $45.97M+22.4% | $37.55M+28.2% | $29.29M+21.0% | $24.2M+47.6% | ||
| —— | —— | —— | -$108.14M-0.3% | ||
| $1.59M+17.3% | $1.36M+122% | $609K-23.4% | $795K-27.8% | ||
| —— | -$299.48M-663% | -$39.26M-143% | $91.47M— | ||
| $22.86M-11.6% | $25.85M-84.8% | $170.48M+805% | $18.84M-85.5% | ||
| —— | -$89.48M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
